S 3064, the Relief of Chronic Pain Act of 2025, modifies Medicare Part D coverage to improve access to non-opioid treatments for specific chronic pain conditions. It requires Medicare plans to exempt qualifying non-opioid drugs (approved for conditions like diabetic neuropathy, fibromyalgia, or musculoskeletal pain) from deductibles and place them on the lowest cost-sharing tier starting in 2026. The bill also bans step therapy (requiring opioid use first) and prior authorization for these drugs. This directly affects Medicare beneficiaries with the listed chronic pain conditions who rely on these approved non-opioid medications.
This bill redefines certain health marketplace pools as "employers" under federal law, enabling them to offer group health coverage to members without discriminating based on health status. It requires these pools to provide uniform coverage to all members (including employees and dependents of participating employers), prohibit health-based enrollment barriers, and allow plans offering only prescription or over-the-counter drug coverage as a primary benefit. Key provisions include standardized pricing rules, geographic flexibility for pool operations, and clarifying that participation does not create employer or joint-employer relationships under other laws. The policy directly affects entities forming these pools (e.g., community cooperatives) and their members, such as small business employees and their dependents.
The Break Up Big Medicine Act requires large healthcare companies that own multiple parts of the healthcare system (such as insurance, pharmacies, and physician practices) to divest certain businesses to eliminate conflicts of interest. It prohibits common ownership between entities like health insurers and physician practices, or drug wholesalers and medical providers, mandating divestiture within one year of enactment. Non-compliance would trigger penalties including monthly escrow of 10% of profits, and the bill allows government agencies and individuals to sue for violations. This directly affects the largest health insurance companies, pharmacy benefit managers, and drug distributors that have integrated operations across the healthcare sector.
This bill expands Medicare coverage to include certain pharmacist services in medically underserved areas. It allows pharmacists licensed in their state to provide services that would otherwise be covered if done by a physician (like medication management), specifically in health professional shortage areas or medically underserved regions. Medicare would pay 80% of the physician fee schedule rate for these services, starting January 1, 2027. The bill requires the development of new billing codes for pharmacists under Medicare's physician fee schedule. It directly affects pharmacists working in designated underserved communities and Medicare beneficiaries there.
The PROTECT for Rare Act (S 3551) requires Medicare, Medicaid, and private health insurers to establish an expedited appeal process for coverage denials of drugs treating rare diseases or conditions affecting 200,000 or fewer U.S. individuals. It expands coverage criteria by allowing insurers to consider peer-reviewed medical literature and clinical guidelines - not just FDA-approved labeling - as valid justification for treatment, while excluding uses listed as contraindicated in approved drug labeling or medical references. The law applies to all covered drugs used for rare conditions and takes effect for coverage decisions starting January 1, 2027. This directly affects patients with rare diseases, healthcare providers seeking coverage approvals, and insurers managing drug benefit denials.
Treat and Reduce Obesity Act of 2025 This bill expands Medicare coverage of intensive behavioral therapy for obesity. Specifically, the bill allows coverage for therapy that is provided by (1) a physician who is not a primary care physician; or (2) other health care providers (e.g., physician assistants and nurse practitioners) and approved counseling programs, if provided upon a referral from, and in coordination with, a physician or primary care practitioner. Currently, such therapy is covered only if provided by a primary care practitioner. The bill also allows coverage under Medicare's prescription drug benefit of drugs used for the treatment of obesity or for weight loss management for individuals who are overweight.
The Small Biotech Innovation Act exempts qualifying drugs from Medicare's drug price negotiation program starting in 2029 for small biotech manufacturers that meet specific R&D investment thresholds. To qualify, a company must have five or fewer single-source drugs and spend 30% to 70% of its net revenue on research and development (based on the number of drugs), while not being controlled by a foreign government. Manufacturers must apply annually with financial data and certification of R&D spending, and the exemption ends if the company is acquired by a non-qualifying entity after 2029. This directly affects small U.S.-based biotech firms developing innovative drugs, allowing them to avoid price negotiations under Medicare.
The PrEP Access Act expands Medicare Part B coverage to include pharmacist-provided HIV prevention services, such as pre-exposure prophylaxis (PrEP) counseling, medication administration, and related testing. It directly affects Medicare beneficiaries (primarily seniors) and pharmacists, allowing pharmacists to bill Medicare for these services under state law. Key provisions set payment at 80% of the lesser of actual charges or 85% of physician rates, and prohibit balance billing for these services. The policy change takes effect January 1, 2027, making PrEP more accessible through pharmacy settings.
The PBM Reporting Transparency Act requires the Medicare Payment Advisory Commission (MedPAC) to produce two reports analyzing pharmacy benefit manager (PBM) agreements with Medicare prescription drug plans. The first report, due 2 years after data becomes available, must detail trends in PBM contracts, their impact on beneficiaries' out-of-pocket costs and pharmacy reimbursement rates, and include recommendations. A second report, due 2 years after the first, will track changes in this data over time and provide updated recommendations. This legislation directly affects Medicare drug plan participants by increasing transparency around PBM practices that influence prescription drug costs.
This bill mandates a study by the Government Accountability Office (GAO) to examine how specific contract clauses in health insurance agreements affect competition and costs. It focuses on "anti-steering" clauses (restricting insurers from directing patients to lower-cost providers), "anti-tiering" clauses (blocking tiered provider networks), "all-or-nothing" clauses (forcing inclusion of all providers), and "gag" clauses (preventing price transparency). The study will assess these clauses' impact on healthcare consolidation, consumer prices, access, and whether federal agencies have sufficient resources to enforce antitrust laws against them. The findings must be reported to relevant congressional committees within 18 months of the bill's enactment. This is a procedural study - no immediate policy changes are implemented by the bill itself.
